BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 25049332)

  • 1. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
    Ades F; Zardavas D; Bozovic-Spasojevic I; Pugliano L; Fumagalli D; de Azambuja E; Viale G; Sotiriou C; Piccart M
    J Clin Oncol; 2014 Sep; 32(25):2794-803. PubMed ID: 25049332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
    Stöger H
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
    Gampenrieder SP
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
    McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
    Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
    Nielsen TO; Jensen MB; Burugu S; Gao D; Jørgensen CL; Balslev E; Ejlertsen B
    Clin Cancer Res; 2017 Feb; 23(4):946-953. PubMed ID: 27601592
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.
    Krijgsman O; Roepman P; Zwart W; Carroll JS; Tian S; de Snoo FA; Bender RA; Bernards R; Glas AM
    Breast Cancer Res Treat; 2012 May; 133(1):37-47. PubMed ID: 21814749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients.
    Hashmi AA; Aijaz S; Khan SM; Mahboob R; Irfan M; Zafar NI; Nisar M; Siddiqui M; Edhi MM; Faridi N; Khan A
    World J Surg Oncol; 2018 Jan; 16(1):1. PubMed ID: 29291744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    Ann Surg Oncol; 2007 Oct; 14(10):2994-3003. PubMed ID: 17647064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
    Izadi P; Mehrdad N; Foruzandeh F; Reza NM
    Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular taxonomy of luminal breast cancer in 2015].
    Franchet C; Duprez-Paumier R; Lacroix-Triki M
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S34-46. PubMed ID: 26118875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
    Ma CX; Bose R; Ellis MJ
    Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.